Stratos Wealth Partners LTD. raised its position in shares of Teladoc Health Inc (NYSE:TDOC) by 66.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,744 shares of the health services provider’s stock after buying an additional 3,081 shares during the period. Stratos Wealth Partners LTD.’s holdings in Teladoc Health were worth $1,478,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Total Clarity Wealth Management Inc. bought a new stake in shares of Teladoc Health during the fourth quarter valued at approximately $25,000. PrairieView Partners LLC bought a new stake in shares of Teladoc Health during the first quarter valued at approximately $31,000. Pathstone Family Office LLC bought a new stake in shares of Teladoc Health during the first quarter valued at approximately $31,000. Marshall Wace North America L.P. bought a new stake in shares of Teladoc Health during the first quarter valued at approximately $35,000. Finally, Capital Advisory Group Advisory Services LLC bought a new stake in shares of Teladoc Health during the first quarter valued at approximately $36,000. 97.14% of the stock is owned by institutional investors.
In related news, COO David William Sides sold 3,117 shares of the firm’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $216.67, for a total transaction of $675,360.39. Following the sale, the chief operating officer now directly owns 7,299 shares in the company, valued at $1,581,474.33. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William H. Frist sold 370 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $180.00, for a total transaction of $66,600.00. Following the sale, the director now owns 5,788 shares in the company, valued at $1,041,840. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 189,977 shares of company stock worth $36,248,032. 3.42% of the stock is currently owned by company insiders.
TDOC opened at $237.63 on Friday. The firm’s fifty day moving average is $207.13 and its two-hundred day moving average is $158.76. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.14 and a current ratio of 6.14. The firm has a market cap of $17.69 billion, a PE ratio of -185.65 and a beta of 0.44. Teladoc Health Inc has a twelve month low of $54.58 and a twelve month high of $240.00.
Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, July 29th. The health services provider reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.11). Teladoc Health had a negative return on equity of 10.23% and a negative net margin of 13.22%. The firm had revenue of $241.03 million during the quarter, compared to analyst estimates of $220.49 million. During the same quarter last year, the business posted ($0.41) earnings per share. The company’s revenue for the quarter was up 85.0% on a year-over-year basis. Equities analysts forecast that Teladoc Health Inc will post -1.15 EPS for the current fiscal year.
Several analysts have recently commented on TDOC shares. SVB Leerink increased their price target on shares of Teladoc Health from $227.00 to $246.00 and gave the company an “outperform” rating in a research note on Thursday. CSFB increased their price target on shares of Teladoc Health from $152.00 to $165.00 and gave the company a “neutral” rating in a research note on Thursday, April 30th. Deutsche Bank increased their price target on shares of Teladoc Health from $184.00 to $238.00 and gave the company a “buy” rating in a research note on Thursday. Wells Fargo & Co raised their price objective on shares of Teladoc Health from $135.00 to $175.00 in a research note on Thursday. Finally, Cowen reaffirmed a “buy” rating and issued a $197.00 price objective on shares of Teladoc Health in a research note on Wednesday, July 8th. Fifteen investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $195.04.
Teladoc Health Company Profile
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Featured Article: What are the economic characteristics of a bear market?
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health Inc (NYSE:TDOC).
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.